Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials

BACKGROUND: Chemoradiotherapy with durvalumab consolidation has yielded excellent results in stage III non-small-cell lung cancer (NSCLC). Therefore, it is essential to identify patients who might benefit from a surgical approach. MATERIAL AND METHODS: Data from 437 patients with operable stage III...

Descripción completa

Detalles Bibliográficos
Autores principales: König, D., Schär, S., Vuong, D., Guckenberger, M., Furrer, K., Opitz, I., Weder, W., Rothschild, S.I., Ochsenbein, A., Zippelius, A., Addeo, A., Mark, M., Eboulet, E.I., Hayoz, S., Thierstein, S., Betticher, D.C., Ris, H.-B., Stupp, R., Curioni-Fontecedro, A., Peters, S., Pless, M., Früh, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011017/
https://www.ncbi.nlm.nih.gov/pubmed/35398718
http://dx.doi.org/10.1016/j.esmoop.2022.100455

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9011017/
https://www.ncbi.nlm.nih.gov/pubmed/35398718
http://dx.doi.org/10.1016/j.esmoop.2022.100455

Ejemplares similares